您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (6): 119-123.doi: 10.6040/j.issn.1671-7554.0.2017.338

• • 上一篇    下一篇

中性粒细胞计数与非酒精性脂肪肝关联性的前瞻性队列研究

柳晓涓1,2,蒋正1,2,康凤玲1,2,周苗1,2,林伟强1,2,薛付忠1,2   

  1. 1.山东大学公共卫生学院生物统计学系, 山东 济南 250012;2.山东大学齐鲁生物医学大数据研究中心, 山东 济南 250012
  • 收稿日期:2017-04-18 出版日期:2017-06-10 发布日期:2017-06-10
  • 通讯作者: 薛付忠. E-mail:xuefzh@sdu.edu.cn E-mail:xuefzh@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(81273177);国家自然科学基金青年基金(81400072);山东省自然科学基金(2013HQ047)

Association between neutrophil count and nonalcoholic fatty liver disease:a prospective cohort study

LIU Xiaojuan1,2, JIANG Zheng1,2, KANG Fengling1,2, ZHOU Miao1,2, LIN Weiqiang1,2, XUE Fuzhong1,2   

  1. 1. Department of Biostatistics, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    2. Cheeloo Research Center for Biomedical Big Data, Shandong University, Jinan 250012, Shandong, China
  • Received:2017-04-18 Online:2017-06-10 Published:2017-06-10

PDF (PC)

300

摘要： 目的 探讨中性粒细胞计数与非酒精性脂肪肝(NAFLD)的关联性。 方法 基于大规模健康管理队列,针对队列基线中无NAFLD的15 463例健康体检对象随访,平均随访时间2.54年,随访结局为发生NAFLD;将基线中性粒细胞计数根据四分位数由低到高划分为4个组段(Q1、Q2、Q3、Q4);采用多元Cox回归计算中性粒细胞计数与NAFLD关联性的相对危险度(HR)。 结果 随访期间3 846人被诊断为NAFLD。Cox结果显示,以Q1为参照,在调整年龄、性别后,中性粒细胞计数的Q2、Q3、Q4三个组段的HR(95%CI)分别为1.265(1.057,1.514)、1.446(1.214,1.724)、1.605(1.350,1.907),上述基础上再调整谷丙转氨酶和γ-谷酰胺转酞酶后,Q2、Q3、Q4三个组段的HR(95%CI)分别为1.264(1.056,1.512)、1.434(1.202,1.710)、1.582(1.330,1.882),进一步调整血脂四项、空腹血糖、体质量指数(BMI)和高血压后,HR(95%CI)分别为1.181(0.986,1.415)、1.189(0.995,1.420)、1.226(1.026,1.464)。 结论 中性粒细胞计数是NAFLD发病的独立危险因素。

关键词: 中性粒细胞计数, 队列研究, Cox回归, 健康管理人群, 非酒精性脂肪肝

Abstract: Objective To explore the longitudinal association between neutrophil count and nonalcoholic fatty liver disease(NAFLD). Methods The cohort consisted of 15 463 non-NAFLD individuals at baseline who were followed for the incident of NAFLD. Cox model was applied to calculate the hazard ratio(HR)and its 95% confidence intervals(95%CI)of quantiles(Q1, Q2, Q3 and Q4)of neutrophil count predicting NAFLD. Results During the follow-up, 3 846 new cases of NAFLD occurred. With Q1 as reference group, after adjusting for age and gender, the HRs(95%CI)of Q2, Q3, and Q4 were 1.265(1.057,1.514), 1.446(1.214,1.724)and 1.605(1.350,1.907), respectively. On the basis of previous model, alanine aminotransferase and gamma glutamyltransferase were added into the model, and the HRs(95%CI)of Q2, Q3, and Q4 were 1.264(1.056,1.512), 1.434(1.202,1.710)and 1.582(1.330,1.882), respectively. After adding BMI, systolic pressure, diastolic pressure, fasting glucose and blood lipids into the model, the HRs(95%CI)were 1.181(0.986,1.415), 1.189(0.995,1.420)and 1.226(1.026,1.464), respectively. Conclusion Neutrophil count is an independent risk factor for the incidence of NAFLD.

Key words: Neutrophil count, Cox regression, Health management population, Nonalcoholic fatty liver disease, Cohort study

中图分类号: 

  • R575.5
[1] Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015[J]. World J Hepatol, 2015, 7(30): 2962-2967.
[2] Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease[J]. Atherosclerosis, 2015, 239(1): 192-202.
[3] Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28(Suppl 1): 11-17.
[4] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1): 204-210.
[5] Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J]. J Hepatol, 2005, 43(3): 508-514.
[6] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363(14): 1341-1350.
[7] Choi SY, Kim D, Kim HJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans[J]. Am J Gastroenterol, 2009, 104(8): 1953-1960.
[8] Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease[J]. Ann Hepatol, 2009, 8(Suppl 1): S40-S43.
[9] Park HE, Kwak MS, Kim D, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study[J]. J Clin Endocrinol Metab, 2016, 101(8): 3134-3143.
[10] Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29(1): 42-51.
[11] Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines[J]. J Gastroenterol Hepatol, 2007, 22(6): 778-787.
[12] Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010:(published in Chinese on Chinese Journal of Hepatology, 2010; 18:163-166)[J]. J Dig Dis, 2011, 12(1): 38-44.
[13] 申振伟, 季晓康, 王庆莲, 等. 非酒精性脂肪肝与慢性肾脏病关系的回顾性队列研究[J]. 山东大学学报(医学版), 2016, 54(7): 43-49. SHEN Zhenwei, JI Xiaokang, WANG Qingliang, et al. Association between nonalcoholic fatty liver disease and chronic kidney disease: a retrospective cohort study[J]. Journal of Shandong University(Health Science), 2016, 54(7): 43-49.
[14] Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease[J]. Eur J Endocrinol, 2005, 152(1): 113-118.
[15] Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2[J]. J Hepatol, 2006, 44(6): 1167-1174.
[16] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J]. Aliment Pharmacol Ther, 2011, 34(3): 274-285.
[17] Lizardi-Cervera J, Chavez-Tapia NC, Pérez-Bautista O, et al. Association among C-reactive protein, fatty liver disease, and cardiovascular risk[J]. Dig Dis Sci, 2007, 52(9): 2375-2379.
[18] Kogiso T, Moriyoshi Y, Shimizu S, et al. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population[J]. J Gastroenterol, 2009, 44(4): 313-321.
[19] Dogru T, Ercin CN, Erdem G, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2008, 103(12): 3217-3218.
[20] Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis[J]. Hepatogastroenterology, 2005, 52(65): 1549-1553.
[21] Lee YJ, Lee HR, Shim JY, et al. Relationship between white blood cell count and nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42(12): 888-894.
[22] Alkhouri N, Morris-Stiff G, Campbell C, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Liver Int, 2012, 32(2): 297-302.
[23] Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance[J]. Biochim Biophys Acta, 2014, 1842(3): 446-462.
[24] Kaur H, Adams-Huet B, Smith G, et al. Increased neutrophil count in nascent metabolic syndrome[J]. Metab Syndr Relat Disord, 2013, 11(2): 128-131.
[25] Wang JB, Zhang YJ, Guan J, et al. Enhanced syndecan-1 expression on neutrophils in patients with type 2 diabetes mellitus[J]. Acta Diabetologica, 2012, 49(1): 41-46.
[26] Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art[J]. World J Gastroenterol, 2014, 20(37): 13306-13324.
[27] Bi WR, Yang CQ, Shi Q, et al. Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes[J]. Genet Mol Res, 2014, 13(3): 5880-5891.
[28] Frith J, Day CP, Henderson E, et al. Non-alcoholic fatty liver disease in older people[J]. Gerontology, 2009, 55(6): 607-613.
[29] Zhang T, Zhang C, Zhang Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study[J]. Atherosclerosis, 2015, 240(1): 144-148.
[30] Zhang T, Zhang Y, Zhang C, et al. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study[J]. PLoS One, 2014, 9(5): e96651. doi: 10.1371/journal.pone.0096651.
[31] Wang S, Zhang C, Zhang G, et al. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study[J]. BMJ Open, 2016, 6(6): e010342. doi: 10.1136/bmjopen-2015-010342.
[32] Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis[J]. Annu Rev Pathol, 2010, 5: 145-171. doi: 10.1146/annurev-pathol-121808-102132.
[33] Poniachik J, Csendes A, Diaz JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease[J]. Cytokine, 2006, 33(5): 252-257.
[34] Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men[J]. J Gastroenterol Hepatol, 2004, 19(6): 694-698.
[35] 张莉, 宋海燕, 季光. 非酒精性脂肪肝代谢调控与炎症反应的共同通路[J]. 中华肝脏病杂志, 2011,19(5): 395-397. ZHANG Li, SONG Haiyan, JI Guang. The joint pathway of metabolism and inflammation in nonalcoholic fatty liver disease[J]. Chinese Journal of Hepatology, 2011, 19(5): 395-397.
[36] Botezelli JD, Mora RF, Dalia RA, et al. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet[J]. Lipids Health Dis, 2010, 9: 116. doi: 10.1186/1476-511X-9-116.
[1] 逄锦宏,苏萍,乔俊鹏,陈巧巧,陈学禹,赵颖颖,施婕,孙晓茹,李秋春,何蕊言,范轶欧,迟蔚蔚. 老年人群可改变心血管危险因素聚集模式与脑卒中的关联[J]. 山东大学学报 (医学版), 2025, 63(9): 11-19.
[2] 王乐,罗清馨,吴思佳,吴雨桐,葛祎蕾,俞一凡,韦云,吉寒冰,刘铁梅,张紫妍,修佳伟,薛付忠,李洪凯. 虚弱和癫痫关联研究:前瞻性队列和孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(9): 20-30.
[3] 陈莹莹,王鲁,胡锡峰,朱高培,薛付忠. 基于贝叶斯网络的2型糖尿病患者并发脑卒中风险预测[J]. 山东大学学报 (医学版), 2025, 63(8): 94-102.
[4] 于晴晴,常开锋,李吉庆,张凯,付苹,刘晓雯,赵英淇,薛付忠. 中老年人群高血压在非甾体抗炎药暴露与心脑血管疾病风险关联中的中介分析[J]. 山东大学学报 (医学版), 2023, 61(8): 79-85.
[5] 许天旗,常娜,张帅,李莎,矫秉轩,于鑫鑫,王锡明. 非酒精性脂肪肝识别基于CTA颈动脉高危斑块[J]. 山东大学学报 (医学版), 2023, 61(12): 36-43.
[6] 杨雪梅,李娟,王一凡,李培龙,王允山,杜鲁涛,王传新. 3-lncRNAs预后模型在HER2阳性乳腺癌预后评价中的意义[J]. 山东大学学报 (医学版), 2020, 58(5): 69-76.
[7] 李明卓,孙秀彬,王春霞,杨洋,刘新辉,刘言训,薛付忠,袁中尚. 血脂正常人群HDL-C纵向变化与冠心病的关联性分析:一项回顾性队列研究[J]. 山东大学学报 (医学版), 2019, 57(8): 110-116.
[8] 徐源佑,杨亚超,王春霞,马晓天,薛付忠,刘言训,王萍. 基于体检队列的胃炎风险预测模型[J]. 山东大学学报 (医学版), 2019, 57(6): 112-116.
[9] 周苗,卞伟玮,柳晓涓,康凤玲,薛付忠,刘静. 嗜碱性粒细胞百分比与慢性肾脏病关系的回顾性队列研究[J]. 山东大学学报 (医学版), 2018, 56(3): 85-90.
[10] 曹瑾,季晓康,孙秀彬,蒋正,薛付忠. γ-谷氨酰转肽酶与高尿酸血症关系的队列分析[J]. 山东大学学报（医学版）, 2017, 55(6): 124-128.
[11] 张光,王广银,吴红彦, 张红玉,王停停,李吉庆,李敏,康凤玲,刘言训,薛付忠. 健康管理人群高脂血症风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 72-76.
[12] 李江冰,宋心红,林海燕,张冬芝,李向一,许艺博,王丽,薛付忠. 健康管理人群缺血性异常心电图的影响因素[J]. 山东大学学报（医学版）, 2017, 55(6): 77-81.
[13] 孙苑潆,杨亚超,曲明苓,陈雁敏,李敏,王淑康,薛付忠,刘云霞. 健康管理人群代谢综合征发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 87-92.
[14] 李敏,王春霞,夏冰,朱茜,孙苑潆,王淑康,薛付忠,贾红英. 健康管理人群脑卒中风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 93-97.
[15] 蒋正,申振伟,张光,李润滋,曹瑾,王丽,薛付忠,刘言训. 基于体检人群的非酒精性脂肪肝筛查工具的建立[J]. 山东大学学报（医学版）, 2017, 55(6): 114-118.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发